An Update on the "Novel" and Direct Oral Anticoagulants, and Long-Term Anticoagulant Therapy.

  title={An Update on the "Novel" and Direct Oral Anticoagulants, and Long-Term Anticoagulant Therapy.},
  author={Mia Djulbegovic and Alfred Ian Lee},
  journal={Clinics in chest medicine},
  volume={39 3},
Update on Management of Portal Vein Thrombosis and the Role of Novel Anticoagulants
Existing clinical data does not support routine anticoagulation of cirrhotic patients with asymptomatic PVT in the absence of underlying cancer, and an emerging body of clinical evidence now suggests that direct-acting oral antICOagulants may be used safely and effectively in PVT.
Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): An update
Modifications of the existing coagulation tests catering to this unmet need for quantification of DOAC activity have been reviewed and promising results have been given but are prohibitively priced.
Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis.
Given that the risk of VTE recurrence is much higher than the calculated threshold for treatment, extended thromboprophylaxis should be considered in all patients with unprovoked VTE who do not have increased bleeding risk.
A Mini-Review: Clinical Development and Potential of Aptamers for Thrombotic Events Treatment and Monitoring
The unique opportunity for aptamer uses in thrombotic events has sparked a considerable amount of research in the area, and some of the most recent developments in using aptamers for anticoagulation monitoring are highlighted.
Bleeding assessment in oral surgery: A cohort study comparing individuals on anticoagulant therapy and a non-anticoagulated group.
  • A. RochaS. Oliveira T. Silva
  • Medicine
    Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • 2019
Management of patients taking antithrombotic drugs before dental surgery
The threshold model revisited
The threshold model is reformulated and it is found that M t ≤ P t, which may explain differences between normative models and actual behaviour in practice, and generates decision thresholds that could be descriptively more accurate.
Venous Thromboembolism Treatment and Prevention in Cancer Patients: Can We Use Pills Yet?
In the perioperative setting, for patients undergoing major surgery with an active cancer, the authors prefer pharmacologic thromboprophylaxis with LMWH, although there is some emerging evidence that DOACs may be safe in this setting.


Meta‐analysis of the efficacy and safety of new oral anticoagulants in patients with cancer‐associated acute venous thromboembolism
The recently introduced new oral anticoagulants (NOACs) have the potential to be alternative options for patients with VTE, as these drugs share practical advantages with LMWH, are administered orally, and had similar efficacy to VKAs but a lower bleeding risk in phase 3 studies in the general VTE population.
Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
The new oral anticoagulants (NOACs), which include dabigatran, rivaroxaban, apixaban, and edoxaban, are poised to replace warfarin for treatment of the majority of patients with venous
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
The efficacy and safety of DOACs were consistent in patients with pulmonary embolism, deep venous thrombosis, a body weight ≥100 kg, moderate renal insufficiency, an age ≥75 years, and cancer.
Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD.
The use of NOACs in select patients with CKD demonstrates efficacy and safety similar to those with VKAs, and proactive postmarketing surveillance and further studies are pivotal to further define the rational use of these agents.
Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study
In this cohort of 200 patients with active cancer and CAT the rates of new or recurrent VTE and major bleeding were comparable to the cancer subgroup analysis from the EINSTEIN studies, and safety and efficacy is preserved, compared with past-published experience with LMWH.
Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
For the treatment of acute venous thromboembolism, a fixed dose of dabigatran is as effective as warfarin, has a safety profile that is similar to that of warfar in, and does not require laboratory monitoring.